Analyst James Gordon of J.P. Morgan maintained a Buy rating on AstraZeneca (AZN – Research Report), retaining the price target of p14,000.00.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
James Gordon has given his Buy rating due to a combination of factors that indicate a positive outlook for AstraZeneca. The company is expected to report strong Q2 2025 results, with both revenues and core EPS projected to grow by 11% in local currency terms. This growth is driven by robust product sales, particularly in the Oncology and Alliance Revenues segments, which are anticipated to increase by 13% and 42% respectively.
Additionally, AstraZeneca’s financial guidance for 2025 is likely to be reiterated, with expectations of high-single-digit revenue growth and low-double-digit core EPS growth. The improved foreign exchange outlook, resulting from a weaker dollar, could lead to slight upgrades in revenue and EPS forecasts. These factors, coupled with effective cost management and strategic product growth, support the Buy rating recommendation.
Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AZN in relation to earlier this year.